Skip to main content
. 2008 Apr;172(4):1030–1042. doi: 10.2353/ajpath.2008.070605

Figure 7.

Figure 7

A: Differences of GFAP protein levels in control and dispase-injected eyes, receiving saline or tezosentan (each group, n = 4), were evaluated with two-way analysis of variance. Tezosentan did not increase GFAP protein in control mice. Dispase injection (0.3 U/μl) produced a significant increase of GFAP protein (P < 0.01). This increase was not affected by tezosentan treatment. Bands corresponding to a pair of saline- and tezosentan-treated dispase-injected eyes showed similar immunostaining. B: A large increase of GFAP protein followed RD. Tezosentan treatment significantly reduced these levels. Paired t-test (n = 8 pairs, P < 0.0004). The bands corresponding to a pair of saline- and tezosentan-treated RD samples illustrate this large reduction.